Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Washington University School of Medicine
City of Hope Medical Center
Children's Oncology Group
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Children's Oncology Group
Medical University of Vienna
M.D. Anderson Cancer Center
Nationwide Children's Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
The Hospital for Sick Children
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
University of California, San Francisco
Augusta University
Augusta University
The University of Texas Health Science Center, Houston
Hoffmann-La Roche
Jazz Pharmaceuticals
University of Florida
Seattle Children's Hospital
Seattle Children's Hospital
Vastra Gotaland Region
Seattle Children's Hospital
St. Jude Children's Research Hospital
Universitätsklinikum Hamburg-Eppendorf
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
Pediatric Brain Tumor Consortium
European Organisation for Research and Treatment of Cancer - EORTC
Nationwide Children's Hospital